See our full UK buyer's guide for IGF-1 LR3
Nat Rev Drug Discovery 20:309325 Narita Y, Arakawa Y, Yamasaki F, Nishikawa R, Aoki T, Kanamori M, Nagane M, Kumabe T, Hirose Y et al (2019) A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma
"Whilst human studies demonstrating an impact on cognitive decline are still lacking, the current evidence points towards these drugs having a preventative effect, rather than in patients with established cognitive impairment," says Cork
Injection timing is typically 30-60 minutes after training on workout days
There was a significant between-study heterogeneity ( I 2 = 539 %, P = 0034) in which the study location and duration of studies were revealed as the sources of heterogeneity following subgroup analysis